NCT00294931View on ClinicalTrials.gov

Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

May 31, 2007

Study Completion Date

January 31, 2009

Conditions
Carcinoma, Small Cell Lung
Interventions
DRUG

irinotecan

DRUG

carboplatin

DRUG

bevacizumab

Trial Locations (4)

33901

Florida Cancer Specialists, Fort Myers

37023

Tennessee Oncology, PLLC, Nashville

37404

Chattanooga Oncology Hematology Associates, Chattanooga

45242

Oncology Hematology Care, Cincinnati

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER

NCT00294931 - Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter